A novel approach to analyzing fMRI and SNP data via parallel independent component analysis

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 6511, Issue PART 1, 2007, Pages

  Jingyu, Liu ^a   Pearlson, Godfrey ^b   Calhoun, Vince ^a,b,c   Windemuth, Andreas ^d  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b INSTITUTE OF LIVING   (United States)

^c MSC01 1070   (United States)

^d Genomas Inc   (United States)

Author keywords

Brain functionality; Correlation; Functional magnetic resonance imaging; Independent component analysis; Single nucleotide polymorphism; SNP association

Indexed keywords

BRAIN; ENZYMES; INDEPENDENT COMPONENT ANALYSIS; MODAL ANALYSIS; NUCLEOTIDES; POLYMORPHISM;

BRAIN FUNCTIONALITY; CONTROL GROUPS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; SINGLE NUCLEOTIDE POLYMORPHISM; SNP ASSOCIATION;

MAGNETIC RESONANCE IMAGING;

EID: 35148813173     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.709344     Document Type: Conference Paper

References (70)

1. J. Gallinat and A. Heinz, "Combination of multimodal imaging and molecular genetic information to investigate complex psychiatric disorders". Pharmacopsychiatry. 39 Suppl 1: p. S76-9 (2006).
2. A.R. Hariri and D.R. Weinberger, "Imaging genomics". Br Med Bull. 65: p. 259-70 (2003).
3. C. Lee, T.H. McGlashan, and S.W. Woods, "Prevention of schizophrenia: can it be achieved?" CNS Drugs. 19(3): p. 193-206 (2005).
4. S.B. Brahmbhatt, et al., "Neural correlates of verbal and nonverbal working memory deficits in individuals with schizophrenia and their high-risk siblings". Schizophr Res, (2006).
5. M.R. Johnson, et al., "A functional magnetic resonance imaging study of working memory abnormalities in schizophrenia". Biol Psychiatry. 60(1): p. 11-21 (2006).
6. M. Assaf, et al., "Abnormal object recall and anterior cingulate overactivation correlate with formal thought disorder in schizophrenia". Biol Psychiatry. 59(5): p. 452-9 (2006).
7. P.C. Tu, et al., "Neural correlates of antisaccade deficits in schizophrenia, an fMRI study". J Psychiatr Res, (2006).
8. S.D. Detera-Wadleigh and F.J. McMahon, "G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis". Biol Psychiatry. 60(2): p. 106-14 (2006).
9. T.E. Goldberg, et al., "The g72/g30 gene complex and cognitive abnormalities in schizophrenia". Neuropsychopharmacology. 31(9): p. 2022-32 (2006).
10. K.G. Bath and F.S. Lee, "Variant BDNF (Val66Met) impact on brain structure and function". Cogn Affect Behav Neurosci. 6(1): p. 79-85 (2006).
11. B.C. Ho, et al., "Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers". Arch Gen Psychiatry. 63(7): p. 731-40 (2006).
12. S. Numata, et al., "Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia". J Neural Transm, (2006).
13. D.J. Porteous, et al., "The genetics and biology of DISCI - an emerging role in psychosis and cognition". Biol Psychiatry. 60(2): p. 123-31 (2006).
14. M.J. Owen, N. Craddock, and M.C. O'Donovan, "Schizophrenia: genes at last?" Trends Genet. 21(9): p. 518-25 (2005).
15. G. Ruano, Physiogenomics: Integrating Systems Engineering and Nanotechnology for Personalized Medicine, in The Biomedical Engineering Handbook, J. Bronzino, Editor, 2005.
16. G. Ruano, et al., "Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis". Pharmacogenomics. 6(8): p. 865-72 (2005).
17. G. Ruano, et al., "Apolipoprotein Al genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training". Atherosclerosis. 185(1): p. 65-9 (2006).
18. P. Derosse, et al., "Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia". Biol Psychiatry, (2006).
19. G. Ruano, et al., "Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction". Nutr Metab (Lond). 3: p. 20 (2006).
20. G. Ruano, S. Zollner, and J.W. Goethe, Drug-Induced Metabolic Syndrome (DIMS) in Psychiatry: A Diagnostic Need Uniquely Suited to Pharmacogenomics, in Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine, S.H.Y. Wong, M. Linder, and R.J. Valdes, Editors, AACC press: Washington, DC. p. 277-282, 2006.
21. V.D. Calhoun and T. Adali, "Unmixing fMRI with independent component analysis". IEEE Eng Med Biol Mag. 25(2): p. 79-90 (2006).
22. V.D. Calhoun, et al., "A method for multitask fMRI data fusion applied to schizophrenia". Hum Brain Mapp. 27(7): p. 598-610 (2006).
23. V.D. Calhoun, et al., "fMRI activation in a visual-perception task: network of areas detected using the general linear model and independent components analysis". Neuroimage. 14(5): p. 1080-8 (2001).
24. V.D. Calhoun, et al, "Spatial and temporal independent component analysis of functional MRI data containing a pair of task-related waveforms". Hum Brain Mapp. 13(1): p. 43-53 (2001).
25. M.J. McKeown, et al., "Analysis of fMRI data by blind separation into independent spatial components". Hum Brain Mapp. 6(3): p. 160-88 (1998).
26. M.J. McKeown and T.J. Sejnowski, "Independent component analysis of fMRI data: examining the assumptions". Hum Brain Mapp. 6(5-6): p. 368-72 (1998).
27. S.I. Lee and S. Batzoglou, "Application of independent component analysis to microarrays". Genome Biol. 4(11): p. R76 (2003).
28. W. Liebermeister, "Linear modes of gene expression determined by independent component analysis". Bioinformatics. 18(1): p. 51-60 (2002).
29. B.D. Home and N.J. Camp, "Principal component analysis for selection of optimal SNP-sets that capture intragenic genetic variation". Genet Epidemiol. 26(1): p. 11-21 (2004).
30. Z. Lin and R.B. Altman, "Finding haplotype tagging SNPs by use of principal components analysis". Am J Hum Genet. 75(5): p. 850-61 (2004).
31. M. Gaeta and J.L. Lacoume. "Sources separation without a priori knowledge: The maximum likelihood solution", in EUSIPCO, Barcelona, Spain, 1990.
32. D.T. Pham, P. Garrat, and C. Juttten. "Separation of a mixture of independent sources through a maximum likelihood approach", in EUSIPCO, Brussels,Belgium, 1992.
33. A.J. Bell and T.J. Sejnowski, "An information-maximization approach to blind separation and blind deconvolution". Neural Comput. 7(6): p. 1129-59 (1995).
34. A. Hyvirinen and E. Oja, "A fast fixed-point algorithm for independent component analysis". Neural Computation. 9(7): p. 1483-1492 (1999).
35. J.F. Cardoso and A. Soloumiac, "Blind Beamforming for Non Gaussian Signals". Radar and Signal Processing, IEE Proceedings F. 140(6): p. 362-370 (1993).
36. J.F. Cardoso, "Infomax and maximum likelihood for blind source separation". IEEE Signal Processing Letters. 4(4): p. 112-114 (1997).
37. M.B. First, et al., Structured Clinical interview for DSM-IV axis I disorders-patient edition (SCID-I/P, Version 2.0). 1995, Biometrics Research Department, New York State Psychiatric Institute: New york.
38. K.A. Kiehl, et al., "An adaptive reflexive processing model of neurocognitive function: supporting evidence from a large scale (n = 100) fMRI study of an auditory oddball task". Neuroimage. 25(3): p. 899-915 (2005).
39. L. Freire and J.F. Mangin, "Motion correction algorithms may create spurious brain activations in the absence of subject motion". Neuroimage. 14(3): p. 709-22 (2001).
40. K. Friston, et al., "Spatial Registration and Normalization of Images". Hum Brain Mapp. 2: p. 165-189 (1995).
41. J.B. Fan, et al., "Highly parallel SNP genotyping". Cold Spring Harb Symp Quant Biol. 68: p. 69-78 (2003).
42. A. Oliphant, et al., "BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping". Biotechniques. Suppl: p. 56-8, 60-1 (2002).
43. H. Akaike, "A new look at statistical model identification". IEEE Trans Automatic Control. 19: p. 716-726 (1974).
44. A. Dawy, et al. "A Novel Gene Mapping Algorithm Based on Independent Component Analysis", in IEEE International Conference on Acoustics, Speech, and Signal Processing, Philadelphia, PA, USA, 2005.
45. P. Alaupovic, "Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins". Methods Enzymol. 263: p. 32-60 (1996).
46. M.G. Baroni, et al., "Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD". BMC Med Genet. 4: p. 8 (2003).
47. H. Arai, et al., "Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000". J Atheroscler Thromb. 12(5): p. 240-50 (2005).
48. L. Allard, et al., "ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke". Proteomics. 4(8): p. 2242-51 (2004).
49. A. Stancakova, et al., "Effect of gene polymorphisms on lipoprotein levels in patients with dyslipidemia of metabolic syndrome". Physiol Res, (2005).
50. S.C. Hamon, et al., "Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster". Hum Hered. 61(2): p. 87-96 (2006).
51. H. Jansen, et al., "Interaction of the common apolipoprotein C-III (APOC3 -482C > T) and hepatic lipase (LIPC -514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARS-II)". Ann Hum Genet. 65(Pt 3): p. 237-43 (2001).
52. F.A. Middleton, et al., "Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia". J Neurosci. 22(7): p. 2718-29 (2002).
53. M.P. Vawter, et al., "Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia". Neurochem Res. 29(6): p. 1245-55 (2004).
54. S.H. Fatemi, et al., "GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum". Schizophr Res. 72(2-3): p. 109-22 (2005).
55. A. Guidotti, et al., "GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon". Psychopharmacology (Berl). 180(2): p. 191-205 (2005).
56. M.E. Danoviz, et al., "Hypertension, obesity and GNB 3 gene variants". Clin Exp Pharmacol Physiol. 33(3): p. 248-52 (2006).
57. A. Eisenhardt, et al., "Association study of the G-protein beta3 subunit C825T polymorphism with disease progression in patients with bladder cancer". World J Urol. 23(4): p. 279-86 (2005).
58. D.J. Muller, et al., "Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia". Eur Neuropsychopharmacol. 15(5): p. 525-31 (2005).
59. A.M. Landau, et al., "Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease". J Exp Med. 202(5): p. 575-81 (2005).
60. J.H. Su, et al., "Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death". Neurobiol Dis. 12(3): p. 182-93 (2003).
61. M. Yucel, et al., "Anterior cingulate dysfunction: implications for psychiatric disorders?" J Psychiatry Neurosci. 28(5): p. 350-4 (2003).
62. C.S. Carter, et al., "Anterior cingulate cortex, error detection, and the online monitoring of performance". Science. 280(5364): p. 747-9 (1998).
63. Goldberg, II, M. Harel, and R. Malach, "When the brain loses its self: prefrontal inactivation during sensorimotor processing". Neuron. 50(2): p. 329-39 (2006).
64. L.J. Otten, R.N. Henson, and M.D. Rugg, "Depth of processing effects on neural correlates of memory encoding: relationship between findings from across- and within-task comparisons". Brain. 124(Pt 2): p. 399-412 (2001).
65. A. Bonner-Jackson, et al., "The influence of encoding strategy on episodic memory and cortical activity in schizophrenia". Biol Psychiatry. 58(1): p. 47-55 (2005).
66. K.F. Berman, R.F. Zee, and D.R. Weinberger, "Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort". Arch Gen Psychiatry. 43(2): p. 126-35 (1986).
67. D.R. Weinberger, K.F. Berman, and R.F. Zee, "Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence". Arch Gen Psychiatry. 43(2): p. 114-24 (1986).
68. W.M. Perlstein, et al., "Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia". Am J Psychiatry. 158(7): p. 1105-13 (2001).
69. K.G. Volz, R.I. Schubotz, and D.Y. von Cramon, "Decision-making and the frontal lobes". Curr Opin Neurol. 19(4): p. 401-6 (2006).
70. K.G. Volz, R.I. Schubotz, and D.Y. von Cramon, "Variants of uncertainty in decision-making and their neural correlates". Brain Res Bull. 67(5): p. 403-12 (2005).